Kenya’s pharmaceutical sector faces a persistent and growing threat which is the circulation of counterfeit drugs. This crisis not only undermines the health of patients but also damages public confidence in the healthcare system and threatens national progress toward universal health coverage. The country’s regulatory efforts have yielded some progress, yet gaps in the supply chain, enforcement challenges, and limited consumer safeguards continue to allow fake drugs to reach patients. In this context, technology presents an essential set of tools that can help close these gaps and provide cost-effective, scalable solutions.
Counterfeit drugs represent a multi-billion shilling parallel economy. A report by the Pharmacy and Poisons Board indicates that 8.0% to 30.0% of medicine in circulation in Kenya may be counterfeit or expired. Drugs that are mainly counterfeited include antibiotics, painkillers and medications for diseases such as diabetes and hypertension. These drugs contain incorrect doses, harmful contaminants or no active ingredients at all. The health impacts include treatment failures, drug resistance, prolonged illness, and in some cases, death.
The technologies that can be used to address this crisis include mobile based drug verification which will enable patients to confirm whether a product is authentic before use. These systems work by printing a unique code on drug packaging that can be verified via SMS or QR code. Benefits derived from employing this strategy include its low costs and easy to deploy nationwide and real time response which empowers consumers directly. Second, blockchain offers an opportunity to digitize and secure the entire pharmaceutical supply chain. By creating a shared, decentralized ledger, every actor in the chain, from the manufacturer to the distributor, can track the movement of medicine in real time. Third, artificial intelligence can be applied to verify the physical characteristics of medicines such as label accuracy.
Despite the availability of various technologies, adoption in Kenya remains limited with major challenges including regulatory inertia with lack of policies mandating digital authentication. Second, cost barriers which is characterized by high costs of acquiring scanners and other technological infrastructure and limited public awareness where most consumers remain unaware of verification options. Strategic recommendations include regulatory mandates such as enforcing serialization and digital labelling for all drugs entering the Kenyan market and incorporating drug authentication in licensing and quality inspections and public-private partnerships which can be fostered by collaborating with mobile network operators and fintech platforms to integrate drug verification into health messaging.
Kenya is at a pivotal moment in its fight against counterfeit drugs. The solutions are available, tested, and applicable at scale. By leveraging mobile technology, blockchain traceability, portable authentication tools, and AI, Kenya can restore trust in its pharmaceutical system, safeguard public health and set a continental example for innovation-driven healthcare safety.
